Lakefront Biotherapeutics (GLPGF) EBT Margin Growth (3y) (2017 - 2026)
Powered by 
Analysis
Lakefront Biotherapeutics (GLPGF) EBT Margin Growth (3y) (2017 - 2026) Analysis & Trends
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBT Margin Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Amgen | 211.50 Bn | 197.51 Bn | 7.24 Bn | 443.00 |
| 2 | Gilead Sciences | 181.29 Bn | 178.11 Bn | 6.22 Bn | -15,548.00 |
| 3 | Vertex Pharmaceuticals | 132.16 Bn | 124.30 Bn | 2.84 Bn | -484.00 |
| 4 | Regeneron Pharmaceuticals | 82.55 Bn | 74.56 Bn | 3.93 Bn | 132.00 |
| 5 | Argenx Se | 61.65 Bn | 56.47 Bn | 1.37 Bn | 6,691.00 |
| 6 | Moderna | 54.65 Bn | 49.52 Bn | 52.00 Mn | -2,054.00 |
| 7 | Alnylam Pharmaceuticals | 34.18 Bn | 30.87 Bn | 992.69 Mn | 9,980.00 |
| 8 | Biogen | 31.36 Bn | 30.07 Bn | 1.96 Bn | -2,399.00 |
| 9 | Roivant Sciences | 30.01 Bn | 30.01 Bn | 1.16 Mn | -1.89 Mn |
| 10 | Lakefront Biotherapeutics | 1.73 Bn | 1.73 Bn | 3.51 Mn | -33,642.00 |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -33,642.00 |
| Mar 31, 2026 | 23,477.00 |
| Dec 31, 2025 | -848,696.00 |
| Sep 30, 2025 | -65,103.00 |
| Jun 30, 2025 | 29,543.00 |
| Mar 31, 2025 | -20,006.00 |
| Dec 31, 2024 | -816,274.00 |
| Sep 30, 2024 | -200.00 |
| Jun 30, 2024 | -14,537.00 |
| Mar 31, 2024 | 4,786.00 |
| Dec 31, 2023 | 105,917.00 |
| Sep 30, 2023 | 2,886.00 |
| Jun 30, 2023 | 9,460.00 |
| Mar 31, 2023 | 2,909.00 |
| Dec 31, 2022 | 4.20 Mn |
| Sep 30, 2022 | -7,335.00 |
| Jun 30, 2022 | 2,487.00 |
| Mar 31, 2022 | 13,853.00 |
| Dec 31, 2021 | -1,861.00 |
| Sep 30, 2021 | -7,041.00 |